Clinical Trials Logo

Chronic Hepatitis clinical trials

View clinical trials related to Chronic Hepatitis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03731923 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Abbreviated MRI for HCC Surveillance

Start date: November 8, 2018
Phase: N/A
Study type: Interventional

This study aims to investigate the clinical feasibility of abbreviated liver MRI for HCC surveillance in a high-risk group.

NCT ID: NCT02772003 Active, not recruiting - Clinical trials for Hepatitis C Infection

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Start date: June 6, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.

NCT ID: NCT02143180 Active, not recruiting - Chronic Hepatitis Clinical Trials

Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study

Start date: May 2014
Phase: N/A
Study type: Observational

Our study is a prospective multicenter research and the aim is to explore a variety of suitable evaluation indicators and criteria for diagnosis of diffuse liver fibrosis, to get the corresponding diagnosis threshold, with the domestic common pathological S stages as the gold standard.

NCT ID: NCT01833611 Active, not recruiting - Chronic Hepatitis Clinical Trials

Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT

Start date: September 2008
Phase: Phase 4
Study type: Interventional

Entecavir (ETV) has shown superior ability to suppress hepatitis B virus (HBV) replication, histology improvement as well as low rate of emergence of resistant mutants. Out of range of clinical recommendations for treatment of chronic hepatitis B (CHB), chronic HBV carriers with persistently normal ALT and viral load more than 10^5 copies/mL have progression of liver disease during long-term follow-up. In addition, certain proportions of these patients do have significant inflammation and fibrosis in liver histology. This study will be able to identify who are at risk of liver disease progression and evaluate efficacy of ETV regarding improvement of liver histology during short-term (1-year) and long-term ETV treatment (3-year).